AACP
KNSA icon

Advantage Alpha Capital Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Advantage Alpha Capital Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,020
Closed -$305K – 137
2025
Q2 		$305K Sell
11,020
-2,577
-19% -$65.6K 0.08% 110
2025
Q1 		$302K Buy
13,597
+4,707
+53% +$96.9K 0.07% 104
2024
Q4 		$176K Sell
8,890
-11,477
-56% -$262K 0.04% 147
2024
Q3 		$509K Sell
20,367
-10,891
-35% -$265K 0.12% 118
2024
Q2 		$584K Buy
+31,258
New +$586K 0.13% 97

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Advantage Alpha Capital Partners's KNSA Position: Q3 2025 in Review

Advantage Alpha Capital Partners sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2025, closing a stake of 11,020 shares — an estimated $305K sold.

Advantage Alpha Capital Partners first reported a position in KNSA in Q2 2024 and held it in 5 quarters. The position peaked at $584K in Q2 2024. 204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

  • Advantage Alpha Capital Partners reported no remaining Kiniksa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 11,020 Kiniksa Pharmaceuticals shares in Q3 2025, an estimated $305K.
  • Advantage Alpha Capital Partners first reported a position in Kiniksa Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • Advantage Alpha Capital Partners's Kiniksa Pharmaceuticals position peaked at $584K in Q2 2024.
  • 204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q3 2025, filed 12 Nov 2025.